Objective: Molecular monitoring using quantitative polymerase chain reaction (qPCR) of
BCR-ABL mRNA transcripts using the international scale (IS) is recommended by the …

In the face of competing first-line treatment options for CML, early prediction of prognosis on
imatinib is desirable to assure favorable survival or otherwise consider the use of a second …

Abstract Abstract 360 Introduction: The lack of a sufficient response to first line imatinib
treatment has been observed in a substantial proportion of CML patients and has been …

Introduction: Real-world treatment and monitoring patterns have not been well documented
among imatinib-treated chronic phase chronic myeloid leukemia (CP-CML) patients. Thus …

Abstract Abstract 505 Background: Therapy with imatinib and other tyrosine kinase inhibitors
leads to complete cytogenetic response (CCyR) in 80-90% of patients in chronic phase (CP) …

Abstract Abstract 3754 Background Imatinib (IM) has dramatically improved the prognosis of
chronic myeloid leukaemia (CML) patients. Some of them will achieve a so-call complete …

Imatinib was the first BCR‐ABL1 tyrosine kinase inhibitor (TKI) developed for the treatment
of patients with chronic myeloid leukemia (CML); subsequently, the introduction of more …

Objectives: Monitoring treatment response is an integral part of chronic myeloid leukemia
(CML) treatment. The guidelines recommend regular monitoring using standard methods …

Molecular monitoring of BCR–ABL transcript levels by real-time quantitative PCR is
increasingly used to assess treatment response in patients with chronic myeloid leukaemia …

The introduction of imatinib has significantly changed prognosis of CML patients. Despite
favourable hematologic and cytogenetic response (CyR) data, patients (pts) on first line …